Form 4: Corcept Therapeutics President Sells Shares

Sentiment:

Insider Transaction (Form 4)


Roberto Wandenkolk Vieira, President, Oncology of Corcept Therapeutics Inc, sold 8,333 shares of common stock on November 2, 2026.

Summary

  • Option exercise/conversion: acquired 8,333 Common Stock at $21.63 ($180,243) on November 2, 2026; holds 12,279 after (Direct).
  • Open-market sale: disposed of 6,657 Common Stock at $80.73 ($537,437) on November 2, 2026; holds 5,622 after (Direct).
  • Open-market sale: disposed of 1,676 Common Stock at $81.52 ($136,632) on November 2, 2026; holds 3,946 after (Direct).
  • Option exercise/conversion: disposed of 8,333 Stock option (right to buy) on November 2, 2026; holds 125,001 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $674,069 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Roberto Wandenkolk Vieira — Officer (President, Oncology)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-11-02Option exercise/conversionCommon Stock8,333$22$180.2K12,279
2026-11-02Open-market saleCommon Stock6,657$81$537.4K5,622
2026-11-02Open-market saleCommon Stock1,676$82$136.6K3,946
2026-11-02Option exercise/conversionStock option (right to buy)8,333——125,001

Key Dates

DateDescription
2026-11-02Option exercise/conversion (8,333 shares)
2026-11-02Open-market sale (6,657 shares)
2026-11-02Open-market sale (1,676 shares)
2026-11-02Option exercise/conversion (8,333 shares)

Keywords

insider transaction, Form 4, CORT, CORCEPT THERAPEUTICS INC, bearish, Roberto Wandenkolk Vieira

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.